Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.7722
Abstract: Key Points Question What is the association of the use of checkpoint inhibitors with the risk of neurological adverse events? Findings In this meta-analysis of 39 trials evaluating the use of checkpoint inhibitors to treat… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.7711
Abstract: This analysis of pooled data from 3 randomized clinical trials evaluates the association between immune-related adverse events and atezolizumab efficacy in patients with advanced non–small cell lung cancer. read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Brain and Behavior"
DOI: 10.1002/brb3.70632
Abstract: The influence of immune cell traits (ICTs) on the onset of multiple brain diseases has been previously investigated; however, it is limited by the sample size or colocalization evidence. Besides, the impact remains inconclusive. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07508-7
Abstract: Background The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, particularly in Asian melanoma. Methods We retrospectively… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16129
Abstract: e16129Background: The role of immune biomarkers in predicting benefits of hepatocellular carcinoma (HCC) was still controversial. We was aimed to investigate the prognostic value of immune biomarke... read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.11510
Abstract: 11510Background: IrAEs are associated with improved clinical outcomes after treatment with ICB in select epithelial malignancies. We hypothesized that sarcoma patients (pts) treated with ICB who de... read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4575
Abstract: 4575Background: The 27-gene immuno-oncology (IO) signature that incorporates expression from activated inflammatory cells, cancer associated fibroblasts, and tumor cells to produce a binary classif... read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s360473
Abstract: Background To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated… read more here.